Paid Clinical Trials Columbia
Discover 215 paid clinical trials in Columbia, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
OSA TherapyReiterative Development and Evaluation Study of OSA Therapy System
Sponsor:
ApniCure, Inc.
Location:
Code:
NCT01634074
Conditions
Obstructive Sleep Apnea
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
TAK-861A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Sponsor:
Takeda
Location:
Code:
NCT05816382
Conditions
Narcolepsy Type 1
Eligibility Criteria
Sex: All
Age: 16 - 70
Healthy Volunteers: Not accepted
Interventions
TAK-861
TasimelteonEvaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
Sponsor:
Vanda Pharmaceuticals
Location:
Code:
NCT04652882
Conditions
Sleep Wake Disorders
Sleep Disorders, Circadian Rhythm
Chronobiology Disorders
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Tasimelteon
Placebo
VA ClavicleCase Series on the Clinical Performance of VA Clavicle and Clavicle Hook Plate 2.7 Systems
Sponsor:
AO Innovation Translation Center
Location:
Code:
NCT04921865
Conditions
Clavicle
Acromioclavicular Joint
Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System
DonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Observational StudyInternational Registry for Men With Advanced Prostate Cancer (IRONMAN)
Sponsor:
Prostate Cancer Clinical Trials Consortium
Location:
Code:
NCT03151629
Conditions
Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Standard of Care
HORIZANTAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo